

# Mattia Galli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9052590/publications.pdf>

Version: 2024-02-01

68  
papers

1,693  
citations

393982

19  
h-index

315357

38  
g-index

69  
all docs

69  
docs citations

69  
times ranked

2171  
citing authors

#	ARTICLE	IF	CITATIONS
1	Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. <i>European Heart Journal</i> , 2015, 36, 1377-1384.	1.0	226
2	Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>Lancet, The</i> , 2021, 397, 1470-1483.	6.3	133
3	Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. <i>European Heart Journal</i> , 2012, 33, 2928-2938.	1.0	95
4	Antiplatelet therapy after percutaneous coronary intervention. <i>EuroIntervention</i> , 2022, 17, e1371-e1396.	1.4	94
5	Coronary Atherosclerotic Phenotype and Plaque Healing in Patients With Recurrent Acute Coronary Syndromes Compared With Patients With Long-term Clinical Stability. <i>JAMA Cardiology</i> , 2019, 4, 321.	3.0	92
6	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. <i>Frontiers in Physiology</i> , 2019, 10, 1347.	1.3	81
7	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. <i>European Heart Journal</i> , 2022, 43, 959-967.	1.0	79
8	A current approach to heart failure in Duchenne muscular dystrophy. <i>Heart</i> , 2017, 103, 1770-1779.	1.2	75
9	Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: A 3-vessel optical coherence tomography study. <i>American Heart Journal</i> , 2014, 167, 59-67.	1.2	74
10	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. <i>Nature Reviews Cardiology</i> , 2019, 16, 113-130.	6.1	73
11	Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study. <i>Journal of Cardiovascular Medicine</i> , 2008, 9, 1004-1010.	0.6	55
12	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 677-686.	1.4	45
13	Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 105-116.	1.4	44
14	Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. <i>Europace</i> , 2020, 22, 538-546.	0.7	36
15	Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 86-93.	1.4	34
16	Where Does Inflammation Fit?. <i>Current Cardiology Reports</i> , 2017, 19, 84.	1.3	32
17	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 963-978.	1.3	27
18	Eosinophil cationic protein and clinical outcome after bare metal stent implantation. <i>Atherosclerosis</i> , 2011, 215, 166-169.	0.4	26

#	ARTICLE	IF	CITATIONS
19	Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 43-56.	1.4	26
20	Colchicine in ischemic heart disease: the good, the bad and the ugly. <i>Clinical Research in Cardiology</i> , 2021, 110, 1531-1542.	1.5	22
21	Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. <i>Trends in Cardiovascular Medicine</i> , 2023, 33, 133-138.	2.3	21
22	Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 128-129.	1.4	19
23	Safety and efficacy of P2Y <sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventions. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 9-21.	1.0	18
24	Electronic Cigarettes and Cardiovascular Risk: Caution Waiting for Evidence. <i>European Cardiology Review</i> , 2019, 14, 151-158.	0.7	18
25	Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 56-64.	1.4	17
26	Optical coherence tomography assessment and quantification of intracoronary thrombus: Status and perspectives. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 172-178.	0.3	16
27	Association between inflammatory biomarkers and in-stent restenosis tissue features: an Optical Coherence Tomography Study. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 917-925.	0.5	15
28	Optimal P2Y <sub>12</sub> inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 20-27.	1.4	14
29	High-risk percutaneous coronary intervention: how to define it today?. <i>Minerva Cardioangiologica</i> , 2018, 66, 576-593.	1.2	14
30	Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. <i>IJC Heart and Vasculature</i> , 2020, 28, 100524.	0.6	13
31	Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 519-528.	1.4	13
32	Early anticoagulation in the current management of NSTEMI-ACS: Evidence, guidelines, practice and perspectives. <i>International Journal of Cardiology</i> , 2019, 275, 39-45.	0.8	12
33	Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 154, 103074.	2.0	12
34	Are Atherogenic Lipoprotein Phenotype and Inflammation Indicative of Plaque Phenotype and Clinical Stability in Coronary Artery Disease?â€”Reply. <i>JAMA Cardiology</i> , 2019, 4, 951.	3.0	10
35	Dual quantitative coronary angiography accurately quantifies intracoronary thrombotic burden in patients with acute coronary syndrome: Comparison with optical coherence tomography imaging. <i>International Journal of Cardiology</i> , 2019, 292, 25-31.	0.8	9
36	Stent Thrombosis With Dual Antithrombotic Therapy in Atrial Fibrillationâ€”ACS/PCI Trials. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1727-1728.	1.2	8

#	ARTICLE	IF	CITATIONS
37	Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3690-3698.	1.1	8
38	Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation. <i>Advances in Therapy</i> , 2021, 38, 2891-2907.	1.3	7
39	Guided selection of antiplatelet therapy in acute coronary syndrome: Impact on outcomes and resource utilization. <i>International Journal of Cardiology</i> , 2021, 345, 36-38.	0.8	7
40	The Role of Antiplatelet Therapy in Patients With MINOCA. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 821297.	1.1	7
41	Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 1273-1285.	1.5	6
42	Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 55-56.	1.4	6
43	Type 2 myocardial infarction: a diagnostic and therapeutic challenge in contemporary cardiology. <i>Internal and Emergency Medicine</i> , 2022, 17, 317-324.	1.0	6
44	Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 728-737.	1.4	6
45	Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. <i>ESC Heart Failure</i> , 2019, 6, 884-888.	1.4	5
46	Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials. <i>Current Opinion in Cardiology</i> , 2021, 36, 390-396.	0.8	5
47	Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 495-498.	1.0	5
48	Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1341-1351.	1.8	5
49	Role of perilipin 2 in microvascular obstruction in patients with ST-elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 633-642.	0.4	3
50	ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrlal fibrillation: the (ORIGAMI) study. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 175-179.	0.6	3
51	Recurrence of angina after ST-segment elevation myocardial infarction: the role of coronary microvascular obstruction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, , 2048872619880661.	0.4	2
52	Aspirin in primary prevention of cardiovascular disease in the elderly. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 326-327.	1.4	2
53	Response to letter to the editor: colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e72-e73.	1.4	2
54	Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3231-3232.	1.2	2

#	ARTICLE	IF	CITATIONS
55	Non-opioid analgesics in patients undergoing percutaneous coronary intervention: hype or hope?. <i>European Heart Journal</i> , 2021, 42, 4037-4039.	1.0	2
56	Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e16-e17.	1.4	2
57	How deep is your lesion? Extreme guideliner V3 intubation through RIMA graft to treat a distal left anterior descending artery stenosis. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 606-608.	0.6	1
58	A case of "resistant" thrombus. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 397-399.	0.6	1
59	Focus on the road to modelling cardiomyopathy in muscular dystrophy. <i>Cardiovascular Research</i> , 2022, 118, 1872-1884.	1.8	1
60	Dabigatran-based dual antithrombotic therapy for patients with atrial fibrillation and ST-elevation myocardial infarction undergoing percutaneous coronary intervention. <i>EuroIntervention</i> , 2021, 17, 443-444.	1.4	1
61	Recurrent chest pain: "what is essential is invisible to the eye"™. <i>European Heart Journal Supplements</i> , 2019, 21, C11-C14.	0.0	0
62	Acceso radial frente a femoral y bivalirudina frente a heparina no fraccionada en pacientes vulnerables con síndrome coronario agudo. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 874-876.	0.6	0
63	Radial versus femoral and bivalirudin versus unfractionated heparin in vulnerable patients with acute coronary syndromes. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 874-876.	0.4	0
64	Dual antiplatelet therapy in the contemporary drug-eluting stents era: from vulnerable stents to vulnerable patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	0
65	Pharmacodynamic profiles of aspirin versus dual-pathway inhibition with either aspirin or clopidogrel among patients with stable atherosclerotic disease. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
66	Estrategia antitrombótica óptima en SCASEST: ¿es la edad sólo un número?. , 2022, 90, 95-97.		0
67	Optimal Antithrombotic Strategy in NSTEMI: Is Age Just a Number?. , 2022, 90, 89-91.		0
68	Dual versus triple antithrombotic therapy for atrial fibrillation-ACS/PCI: One size does not fit all. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	0